

CURRICULUM VITAE DI NICOLA BATTELLI
aggiornato al 24/04/2018

INFORMAZIONI PERSONALI

Cognome / Nome	BATTELLI NICOLA
Anno di nascita	1969
Qualifica	Medico Oncologo
Amministrazione	ASUR Marche A.V.3
Struttura di appartenenza	Ospedale Generale Provinciale di Macerata, ASUR Marche area vasta n°3
Incarico attuale e servizio di afferenza	Direttore U.O.C. Oncologia
Num. Tel. Ufficio	0733 2572881
Fax dell'Ufficio	0733 2572526
E-mail istituzionale	nicola.battelli@sanita.marche.it

TITOLI DI STUDIO E PROFESSIONALI, ESPERIENZE LAVORATIVE, ALTRE CONOSCENZE

Titolo di studio	Laurea in Medicina e Chirurgia																						
Altri titoli di studio e professionali	Specializzazione in Oncologia																						
Esperienze professionali (incarichi ricoperti)	- Da Settembre 2017: Direttore U.O.C. Oncologia, Ospedale di Macerata, Area vasta N°3 - Gennaio 2017- Agosto 2017: Direttore U.O.C. Oncologia, Ospedale di Jesi, Area vasta N°2 - Luglio 2000 - Dicembre 2016: Medico Oncologo, Ospedale di Ancona, Area vasta n°2 - Marzo 1999 – Ottobre 2000: Dirigente Medico I Livello, Oncologia Medica di Ancona																						
Capacità linguistiche (stima della conoscenza linguistica sulla base del Quadro Comune Europeo di Riferimento delle Lingue)	<table><tr><td></td><td colspan="2">Comprensione</td><td colspan="2">Parlato</td><td>Produzione scritta</td></tr><tr><td>Lingua conosciuta</td><td>Ascolto</td><td>Lettura</td><td>Interazione</td><td>Produzione orale</td><td></td></tr><tr><td>Inglese</td><td>B2</td><td>B2</td><td>B1</td><td>B1</td><td>B1</td></tr></table> Legenda livelli: A1/2 Livello base - B1/2 Livello intermedio - C1/2 Livello avanzato						Comprensione		Parlato		Produzione scritta	Lingua conosciuta	Ascolto	Lettura	Interazione	Produzione orale		Inglese	B2	B2	B1	B1	B1
	Comprensione		Parlato		Produzione scritta																		
Lingua conosciuta	Ascolto	Lettura	Interazione	Produzione orale																			
Inglese	B2	B2	B1	B1	B1																		

Capacità nell'uso delle tecnologie	Conoscenza ed uso dei seguenti programmi: Windows XP e precedenti, Pacchetto Office, Power Point, File Maker Pro, Regolo, SAS 8.2, MedCalc, DOSSIER.
Partecipazione a convegni, seminari, workshop ecc.	Ha partecipato a circa 100 congressi nazionali e internazionali in qualità di discussant, relatore e moderatore. Ha partecipato a numerosi corsi (principalmente sulle neoplasie mammarie) invitato come esperto in ambito nazionale. E' autore di diverse pubblicazioni scientifiche molte delle quali pubblicate in riviste internazionali indicizzate.
Attività di docenza	Negli anni 2003, 2005, 2006, 2007, 2011, 2012, 2013, 2014, 2015 è stato docente della Scuola di Specialità in Oncologia Medica dell'Università di Ancona.
Pubblicazioni	1. Mollica V, Di Nunno V, Gatto L, Santoni M, Scarpelli M, Cimadamore A, Lopez-Beltran A, Cheng L, Battelli N, Montironi R, Massari F. Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor. <i>Cancers (Basel)</i> 2019 Jun 14;11(6). Review 2. Di Nunno V, Frega G, Santoni M, Gatto L, Fiorentino M, Montironi R, Battelli N, Brandi G, Massari F. BAP1 in solid tumors. <i>Future Oncol.</i> 2019 Jun; 15(18):2151-2162. doi: 10.2217/fon-2018-0915 Epub 2019 Jun 4. 3. Santoni M, Maiorani G, Faloppi L, Di Nunno V, Gatto L, Massari F, Battelli N. Optimizing renal function and outcome of patients with cT2 renal cell carcinoma <i>Ann Transl Med.</i> 2019 Mar;7(Suppl 1):S39 No abstract available. 4. Di Nunno V, Mollica V, Gatto L, Santoni M, Sorgentoni G, Battelli N, Massari F. Adjuvant therapy in renal cell carcinoma-is pharmacogenomics assessment another element to select our patients? <i>Ann Transl Med.</i> 2019 Mar;7(Suppl 1):S38 No abstract available. 5. Santoni M, Cimadamore A, Cheng L, Lopez-Beltran A, Battelli N, Massari F, Scarpelli M, Galosi AB, Bracarda S, Montironi R. Circulating Tumor Cells in Renal Cell Carcinoma Recent Findings and Future Challenges. <i>Front Oncol.</i> 2019 Apr 5;9:228. No abstract available. 6. Mollica V, Di Nunno V, Gatto L, Santoni M, Cimadamore A, Cheng L, Lopez-Beltran A, Montironi R, Pisconti S, Battelli N, Massari F. Novel Therapeutic Approaches and Targets Currently Under Evaluation for Renal Cell Carcinoma: Waiting for the Revolution <i>Clin Drug Investig.</i> 2019 Jun;39(6):503-519. Review. 7. Massari F, Mollica V, Di Nunno V, Gatto L, Santoni M, Scarpelli M, Cimadamore A, Lopez-Beltran A, Cheng L, Battelli N, Montironi R, Brandi G. The Human Microbiota and Prostate Cancer: Friend or Foe? <i>Cancers (Basel).</i> 2019 Mar 31;11(4). Review 8. Cimadamore A, Cheng M, Santoni M, Lopez-Beltran A, Battelli N, Massari F, Galosi AB, Scarpelli M, Montironi R. New Prostate Cancer Targets for Diagnosis, 9. ,Imaging, and Therapy: Focus on Prostate-Specific Membrane Antigen. <i>Front Oncol</i> 2018 Dec 21;8:653. Review. 10. Santoni M, Conti A, Buti S, Bersanelli M, Foghini L, Piva F, Giulietti M, Lusuardi L, Battelli N. Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: a systematic review and meta-analysis. <i>Immunotherapy.</i> 2018 Nov;10(15): 1303-1313 11. Carrozza F, Santoni M, Piva F, Cheng L, Lopez-Beltran A, Scarpelli M, Montironi R, Battelli N, Tamberi S. Emerging immunotherapeutic strategies targeting telomerases in genitourinary tumors. <i>Crit Rev Oncol Hematol.</i> 2018 Nov;131:1-6. 12. Santoni G, Morelli MB, Amantini C, Battelli N Urinary Markers in Bladder Cancer: An Update <i>Front Oncol.</i> 2018 Sep 7;8:362. 13. Santoni M, Montironi R, Battelli N. <u>Immune Checkpoint Blockade in Advanced</u>

Renal-Cell Carcinoma. N Engl J Med. 2018 Jul 5;379(1):91-2.

14. Giulietti M, Santoni M, Cimadamore A, Carrozza F, Piva F, Cheng L, Lopez-Beltran A, Scarpelli M, **Battelli N**, Montironi R. Exploring Small Extracellular Vesicles for Precision Medicine in Prostate Cancer. Front Oncol. 2018 Jun 13;8:221.
15. Cimadamore A, Gasparrini S, Santoni M, Cheng L, Lopez-Beltran A, **Battelli N**, Massari F, Giunchi F, Fiorentino M, Scarpelli M, Montironi R. Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer. Expert Rev Mol Diagn. 2018 Jul; 18(7):645-655.
16. Santoni M, Massari F, Di Nunno V, Conti A, Cimadamore A, Scarpelli M, Montironi R, Cheng L, **Battelli N**, Lopez-Beltran A. Immunotherapy in renal cell carcinoma: latest evidence and clinical implications. Drugs Context. 2018 Jun 5;7:212528.
17. Massari F, Santoni M, Di Nunno V, Cheng L, Lopez-Beltran A, Cimadamore A, Gasparrini S, Scarpelli M, **Battelli N**, Montironi R. Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies. Cancer Treat Rev. 2018 Jul;68:80-85.
18. Santoni M, Massari F, Piva F, Carrozza F, Di Nunno V, Cimadamore A, Martignetti A, Montironi R, **Battelli N**. Tivozanib for the treatment of renal cell carcinoma. Expert Opin Pharmacother. 2018 Jun;19(9):1021-1025.
19. Santoni M, **Battelli N**, Buti S. Durvalumab in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2018 Mar 1;378(9):869. doi: 10.1056/NEJMc1716426.
20. Massari F, Di Nunno V, Cubelli M, Santoni M, Fiorentino M, Montironi R, Cheng L, Lopez-Beltran A, **Battelli N**, Ardizzoni A. Immune checkpoint inhibitors for metastatic bladder cancer. Cancer Treat Rev. 2018 Mar;64:11-20. doi: 10.1016/j.ctrv.2017.12.007. Epub 2018 Jan 31. Review.
21. Santoni M, Romagnoli E, Saladino T, Foghini L, Guarino S, Capponi M, Giannini M, Cognigni PD, Ferrara G, **Battelli N**. Triple negative breast cancer: Key role of Tumor-Associated Macrophages in regulating the activity of anti-PD-1/PD-L1 agents. Biochim Biophys Acta. 2018 Jan;1869(1):78-84. doi: 10.1016/j.bbcan.2017.10.007. Epub 2017 Nov 7. Review.
22. Ballatore Z, Pistelli M, **Battelli N**, Pagliacci A, De Lisa M, Berardi R, Cascinu S. Everolimus and exemestane in long survival hormone receptor positive male breast cancer: case report. BMC Res Notes. 2016 Nov 28;9(1):497.
23. Pistelli M, Ballatore Z, Santinelli A, Biscotti T, Piva F, Occhipinti G, Della Mora A, Pagliacci A, **Battelli N**, Bastianelli L, De Lisa M, Bracci R, Maccaroni E, Berardi R, Cascinu S. Phosphorylated mTOR is associated to androgen receptor expression in early triple-negative breast cancer. Oncol Rep. 2016 Aug;36(2):755-62. doi: 10.3892/or.2016.4903. Epub 2016 Jun 22.
24. Guerra F, Marchesini M, Contadini D, Menditto A, Morelli M, Piccolo E, **Battelli N**, Pistelli M, Berardi R, Cascinu S, Capucci A. Speckle-tracking global longitudinal strain as an early predictor of cardiotoxicity in breast carcinoma. Support Care Cancer. 2016 Jul;24(7):3139-45. doi: 10.1007/s00520-016-3137-y. Epub 2016 Feb 29.
25. Pistelli M, De Lisa M, Ballatore Z, Caramanti M, Pagliacci A, **Battelli N**, Ridolfi F, Santoni M, Maccaroni E, Bracci R, Santinelli A, Biscotti T, Berardi R, Cascinu S. Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients. BMC Cancer. 2015 Mar 28;15:195. doi: 10.1186/s12885-015-1204-2.
26. Sanna G, Fabi A, Crivellari D, Saracchini S, **Battelli N**, Nisticò C, Capobianco AM, Zampa G, Bottini A, Del Prete S, Simoncini E, Galli A, Matasconi M, Restuccia E, Biganzoli L. Safety and efficacy of bevacizumab in combination with first-line chemotherapy in advanced breast cancer: data from the Italian cohort of the ATHENA trial. Tumori. 2014 Jul-Aug;100(4):432-8. doi: 10.1700/1636.17904.

27. Pistelli M, Caramanti M, Biscotti T, Santinelli A, Pagliacci A, De Lisa M, Ballatore Z, Ridolfi F, Maccaroni E, Bracci R, Berardi R, **Battelli N**, Cascinu S. Androgen receptor expression in early triple-negative breast cancer: clinical significance and prognostic associations. *Cancers (Basel)*. 2014 Jun 27;6(3):1351-62. doi: 10.3390/cancers6031351.
28. Natoli C, Brocco D, Sperduti I, Nuzzo A, Tinari N, De Tursi M, Grassadonia A, Mazzilli L, Iacobelli S, Gamucci T, Vici P. Breast cancer "tailored follow-up" in Italian oncology units: a web-based survey.; "FOLLOW-UP" Study Group. *PLoS One*. 2014 Apr 8;9(4):e94063. doi: 10.1371/journal.pone.0094063. eCollection 2014.
29. Pistelli M, Pagliacci A, **Battelli N**, Santinelli A, Biscotti T, Ballatore Z, Berardi R, Cascinu S. Prognostic factors in early-stage triple-negative breast cancer: lessons and limits from clinical practice. *Anticancer Res*. 2013 Jun;33(6):2737-42.
30. Pestrin M, Bessi S, Puglisi F, Minisini AM, Masci G, **Battelli N**, Ravaoli A, Gianni L, Di Marsico R, Tondini C, Gori S, Coombes CR, Stebbing J, Biganzoli L, Buyse M, Di Leo A. Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept study. *Breast Cancer Res Treat*. 2012 Jul;134(1):283-9. doi: 10.1007/s10549-012-2045-1. Epub 2012 Apr 4.
31. **Battelli N**, Bittoni A, Pagliacci A, Zepponi L, Scartozzi M, Mariotti C, Cascinu S. Doses of capecitabine and oral vinorelbine are not relevant for efficacy in breast cancer patients: an analysis of dose intensity. *Tumori*. 2011 Jul-Aug;97(4):449-53. doi: 10.1700/950.10396.
32. Ménard S, Balsari A, Tagliabue E, Camerini T, Casalini P, Bufalino R, Castiglioni F, Carcangiu ML, Gloghini A, Scalone S, Querzoli P, Lunardi M, Molino A, Mandarà M, Mottolise M, Marandino F, Venturini M, Bighin C, Cancelli G, Montagna E, Perrone F, De Matteis A, Sapino A, Donadio M, **Battelli N**, Santinelli A, Pavesi L, Lanza A, Zito FA, Labriola A, Aiello RA, Caruso M, Zanconati F, Mustacchi G, Barbareschi M, Frisinghelli M, Russo R, Carrillo G; OMERO Group. Biology, prognosis and response to therapy of breast carcinomas according to HER2 score. *Ann Oncol*. 2008 Oct;19(10):1706-12. doi: 10.1093/annonc/mdn369. Epub 2008 Jun 9.
33. Guarneri V, Frassoldati A, Ficarra G, Puglisi F, Andreetta C, Michelotti A, Cresti N, Boni C, Bisagni G, Berardi R, **Battelli N**, Santoro A, Banna G, Bottini A, Di Blasio B, Maiorana A, Piacentini F, Giovannelli S, Jovic G, Conte P. Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer. *Breast Cancer Res Treat*. 2008 Jul;110(1):127-34. Epub 2007 Aug 9.
34. Chan A, Martin M, Untch M, Gil MG, Guillem-Porta V, Wojtukiewicz M, Kellokumpu-Lehtinen P, Sommer HL, Georgoulas V, **Battelli N**, Pawlicki M, Aubert D, Bourlard T, Gasmi J, Villanova G, Petruzelka L; Navelbine Herceptin Project. Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trial. *Br J Cancer*. 2006 Oct 9;95(7):788-93. Epub 2006 Sep 12.
35. **Battelli N**, Massacesi C, Braconi C, Pilone A, Manzione L, Dinota A, Cobelli S, Scanni A, Sturba F, Giacomini G, Morale D, Giorgi F, Tummarello D, Cascinu S. Paclitaxel and epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil for patients with stage IIIC breast cancer with ten or more involved axillary lymph nodes. *Am J Clin Oncol*. 2006 Aug;29(4):380-4.
36. Berardi R, Grilli G, Romagnoli E, Saladino T, Freddari F, Tamburrano T, Galizia E, Carbonari G, Mariani C, Braconi C, Pierantoni C, **Battelli N**, Scartozzi M, Cascinu S. Paraneoplastic syndromes: a review]. *Clin Ter*. 2005 Nov-Dec;156(6):281-8. Review. Italian.
37. Massacesi C, Marcucci F, Boccetti T, **Battelli N**, Pilone A, Rocchi MB, Bonsignori

	M. Low dose-intensity docetaxel in the treatment of pre-treated elderly patients with metastatic breast cancer. <i>J Exp Clin Cancer Res.</i> 2005 Mar;24(1):43-8. 38. Cascinu S, Graziano F, Ferraù F, Catalano V, Massacesi C, Santini D, Silva RR, Barni S, Zaniboni A, Battelli N, Siena S, Giordani P, Mari D, Baldelli AM, Antognoli S, Maisano R, Priolo D, Pessi MA, Tonini G, Rota S, Labianca R. Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD). <i>Ann Oncol.</i> 2002 May;13(5):716-20. 39. Graziano F, Catalano V, Baldelli AM, Giordani P, Testa E, Lai V, Catalano G, Battelli N, Cascinu S. A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer. <i>Ann Oncol.</i> 2000 Oct;11(10):1263-6. 40. Lippe P, Silva RR, Giuliodori L, Cancellieri MA, Battelli N, Massacesi C, Berardi R, Bisonni R, Gesuita R, Cellerino R. Advanced non-small cell lung cancer in the elderly: effective and well tolerated weekly gemcitabine and cisplatin regimen. A pilot study. <i>Minerva Med.</i> 2000 Mar-Apr;91(3-4):53-7. 41. Cascinu S, Frontini L, Comella G, Barni S, Labianca R, Battelli N, Casaretti R, Zonato S, Pirovano M, Catalano G, Cellerino R. Intensive weekly chemotherapy is not effective in advanced pancreatic cancer patients: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). <i>Br J Cancer.</i> 1999 Feb;79(3-4):491-4. 42. Tummarello D, Lippe P, Bracci R, Mari D, Monterubbianesi MC, Battelli N. First line chemotherapy in patients with brain metastases from non-small and small cell lung cancer. <i>Oncol Rep.</i> 1998 Jul-Aug;5(4):897-900. 43. Cascinu S, Catalano V, Baldelli AM, Scartozzi M, Battelli N, Graziano F, Cellerino R. Locoregional treatments of unresectable liver metastases from colorectal cancer. <i>Cancer Treat Rev.</i> 1998 Feb;24(1):3-14. Review. 44. Cascinu S, Battelli N, Graziano F, Ghi M, Silva R, Nacciarriti D, Cellerino R. c-erbB-2 and common prognostic factors in breast cancer patients. <i>Oncol Rep.</i> 1996 Sep;3(5):883-6. 45. Silva RR, Bascioni R, Rossini S, Zuccatosta L, Mattioli R, Pilone A, Delprete S, Battelli N, Gasparini S, Battelli T. A phase II study of mitomycin C, vindesine and cisplatin combined with alpha interferon in advanced non-small cell lung cancer. <i>Tumori.</i> 1996 Jan-Feb;82(1):68-71. 46. Rupoli S, Battelli N, Del Prete S, Salvi A, Cinciripini A, Scortechini AR, Cantori I, Barulli S, Leoni P. [Biologic aspects and clinical use of granulocyte growth factor]. <i>Recenti Prog Med.</i> 1995 Dec;86(12):510-7. Review. Italian. 47. Mattioli R, Silva RR, Battelli N, Manocchi P, Pilone A, Rossini S, Delprete S, Mazzanti P, Bascioni R, Battelli T. Mitomycin C, 5fluorouracil and folinic acid in combination with alpha 2b interferon for advanced colorectal cancer. <i>Tumori.</i> 1993 Dec 31;79(6):393-6. Erratum in: <i>Tumori</i> 1994 Aug 31;80(4):following 314.
Attività di ricerca clinica	STUDI INTERVENTISTICI ATTIVI 1. A-BRAVE (Università di Padova) - Adjuvant treatment for high-risk triple negative breast cancer patients with the anti-PD-L1 antibody Avelumab: a phase III randomized trial. 2. Violette (Astrazeneca) - A phase II, open label, randomised, multi-centre study to assess the safety and efficacy of agents targeting DNA damage repair in combination with olaparib versus olaparib monotherapy in the treatment of metastatic triple negative breast cancer patients stratified by alterations in homologous recombination repair (HRR)-related genes (including BRCA1/2) (VIOLETTE).

3. METEORA II (IBCSG) - A randomized phase II trial of metronomic oral vinorelbine plus cyclophosphamide and capecitabine (VEX) versus weekly paclitaxel as first-line or second-line treatment in patients with ER-positive/HER2-negative advanced or metastatic breast cancer.
4. CLEE011AIT01 - Bioitalee (Novartis) - A phase IIIb, open-label, local, multicenter study of the molecular features of postmenopausal women with hormone receptor-positive (HR+) HER2-negative advanced breast cancer on first-line treatment with ribociclib and letrozole (BioitaLEE).
5. CLEE011A2404 - COMPLEMENT 1 (Novartis) - An open-label, multicenter, phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and pre/postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (aBC) with no prior hormonal therapy for advanced disease.
6. CLEE011A2301 - Monaleesa 2 (Novartis) - A randomized double-blind, placebo-controlled study of LEE011 in combination with Letrozole for the treatment of postmenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer who received no prior therapy for advanced disease.
7. CLEE011E2301 - Monaleesa 7 (Novartis) - A phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with Tamoxifen and Goserelin or an non-steroidal aromatase inhibitor (NSAI) and Goserelin for the treatment of premenopausal women with hormone receptor positive, HER2 negative, advanced breast cancer
8. MK-3475-522 (Merck) - A double blind phase III study of pembrolizumab in combination with chemotherapy as neoadjuvant treatment and pembrolizumab monotherapy as adjuvant treatment for TNBC.
9. The ARIES study (Consorzio Oncotech) - Avelumab as single agent in metastatic or locally advanced urothelial cancer in patients unfit for cisplatin.
10. GOGER 01 (Policlinico Sant'Orsola) - Randomized phase II study of 3 vs 6 courses of neoadjuvant carboplatin-paclitaxel chemotherapy in stage IIIC or IV epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal carcinoma.
11. CINC280A2201 (Novartis) - A phase II, multicenter, three-cohort study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC) who have received one or two prior lines of systemic therapy for advanced/metastatic disease.